On Jun. 19, 2020, GSK announced that a scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine had entered into human clinical trials. Clover announced the initiation of a Phase 1 clinical study evaluating the companyﾒs COVID-19 S-Trimer vaccine (SCB-2019) in combination with GSKs pandemic adjuvant system.